Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Sonoma Pharmaceuticals, Inc. Common Stock

SNOA

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Last trade $0.88
Day change -$0.0002 (-0.02%)
Day range $0.82 – $0.899
Volume 91,402
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.45M
Price / earnings
—
Price / book
0.68×
Price / sales
0.2×
EV / sales
-0.03×
EV / EBITDA
0.33×

Profitability

Earnings per share
-$0.45
Return on assets
-12.5%
Return on equity
-34.33%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.02×
Current ratio
2.99×
Quick ratio
2.29×
Cash ratio
0.98×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$2.66M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SNOA, quarterly periods
Line itemQ1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q3 FY2026 Dec 31, 2025Q2 FY2026 Sep 30, 2025Q1 FY2026 Jun 30, 2025Q4 FY2025 Mar 31, 2025Q3 FY2025 Dec 31, 2024Q2 FY2025 Sep 30, 2024
Revenue$6.41M$5.56M$4.35M$5.6M$4.02M$3.75M$3.56M$3.58M
Cost of revenue$3.83M$3.38M$2.7M$3.48M$2.55M$2.23M$2.29M$2.22M
Gross profit$2.58M$2.18M$1.65M$2.12M$1.46M$1.53M$1.27M$1.36M
Selling, general and administrative$2.02M$1.99M$1.77M$1.88M$1.97M$1.77M$1.87M$1.71M
Research and development$597K$545K$557K$575K$594K$411K$427K$506K
Total operating expenses$2.62M$3.49M$2.33M$2.46M$2.56M$1.38M$2.3M$2.21M
Operating income-$40K-$1.31M-$678K-$337K-$1.1M$147K-$1.03M-$850K
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$330K-$497K-$949K-$731K-$1.24M-$528K-$919K-$463K
Income taxes$0$84K-$130K-$197K-$1K$248K$9K$147K
Net income-$330K-$581K-$819K-$534K-$1.24M-$776K-$928K-$610K
Net income attributable to common shareholders-$330K-$581K-$819K-$534K-$1.24M-$776K-$928K-$610K
EBITDA-$8K-$1.28M-$644K-$301K-$1.06M$178K-$998K-$815K
Basic earnings per share-$0.09-$0.33-$0.48-$0.32-$0.76-$0.48-$0.63-$0.59
Diluted earnings per share-$0.09-$0.33-$0.48-$0.32-$0.76-$0.48-$0.63-$0.59

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

Shares of Netflix, Inc. (NASDAQ: NFLX) shares rose sharply in today’s pre-market trading as the company reported better-than-expected sales for its fourth quarter. Netflix reported fourth-quarter revenue of $8.83 billion, which was up 12.5% year-over-year. The total came in ahead of a Street consensus estimate of $8.72 billion. The company reported fourth-quarter earnings per share of $2.11, which missed a Street consensus estimate of $2.21. The company, meanwhile, added 13.12 million net paid subscribers in the fourth quarter. Netflix shares jumped 10.2% to $542.48 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Getaround, Inc. (NYSE: GETR) gained 50.7% to $0.2771 in pre-market trading after the company announced a new debt facility with Mudrick Capital Management for up to $20 million. Evaxion Biotech A/S (NASDAQ: EVAX) gained 43.2% to $7.15 in pre-market trading after a 13G filing showed Merck & Co reported an 11.4% stake in the company as of December 21, 2023. VS MEDIA Holdings Limited (NASDAQ: VSME) shares jumped 31.7% to $0.4318 in ...

Benzinga

Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer. Lantheus Holdings shares dipped 22.5% to $58.93 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Invivyd, Inc. (NASDAQ: IVVD) shares surged 170% to $4.40 after the company reported positive initial results from ongoing CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the Prevention of COVID-19. Cuentas Inc. (NASDAQ: CUEN) shares climbed 71.6% to $2.37. iCoreConnect Inc. (NASDAQ: ICCT) shares jumped 49.4% to $2.54 after surging over 73% on Friday. ZimVie Inc. (NASDAQ: ZIMV) gained 42.8% to $16.03 after the company disclosed an agreement to sell its spine business to H.I.G. Capital for $375 million. Biomerica, Inc. (NASDAQ: BMRA) climbed 42.4% to $1.41. Biomerica received FDA 510(k) clearance for its Hp Detect Stool Antigen ELISA test, designed to detect the presence of the H. pylori bacteria. Akso Health Group (NASDAQ: AHG) gained 41.6% to $0.8499. Energy Services of America Corporation (NASDAQ: ESOA) surged 35.4% to $4.7399 following FY23 earnings results. LQR House Inc. (NASDAQ: LQR) gained 30.9% to $3.3649. United States Steel Corporation (NYSE: X) rose 26.5% to $49.77 after Nippon Steel announced it will acquire the company for $55 per share in an all-cash transaction. Color Star Technology Co., Ltd. (NASDAQ: ADD) climbed 26.5% to $0.50. ZK International Group Co., Ltd. (NASDAQ: ZKIN) rose 22.3% to $1.26. Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR) shares gained 22.2% to $0.2750 after dipping around 24% on Friday. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) gained 21.3% to $2.96 after the FDA approved the company's Zoryve topical foam, 0.3% for seborrheic dermatitis in individuals nine years and older. Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) climbed 20.5% to $0.6143. Noble Capital Markets ...

Benzinga

Why Arcutis Biotherapeutics Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) rose sharply in pre-market trading after the FDA approved company’s ZORYVE topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and older. Arcutis Biotherapeutics shares gained 25.3% to $3.06 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Banzai International, Inc. (NASDAQ: BNZI) shares gained 120.8% to $13.60 in pre-market trading. The company completed business combination with 7GC & Co on Friday. Royalty Management Holding Corporation (NASDAQ: RMCO) gained 39.8% to $3.51 in pre-market trading after falling around 20% on Friday. Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR) shares gained 45.8% to $0.3282 in pre-market trading after dipping around 24% on Friday. iCoreConnect Inc. (NASDAQ: ICCT) shares climbed 32.4% to $2.25 in pre-market trading after surging over 73% ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 30, 20241-for-20reverse split
Jun 20, 20191-for-9reverse split
Jun 27, 20161-for-5reverse split
Apr 1, 20131-for-7reverse split